The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, severe alopecia areata. Patients from European sites who previously completed a qualifying CTP-543 clinical trial may participate in this study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
407
Twice daily dosing
Number of Participants With Adverse Events as a Measure of Safety
Time frame: 108 weeks
Relative Change From Pre-zero Baseline in Total Severity of Alopecia Tool (SALT) Scores at Week 108
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). This outcome measures the relative Change from Pre-zero Baseline in Total SALT Scores. Relative change from baseline was defined as 100\*(post-baseline value - baseline)/baseline.
Time frame: 108 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Service de Dermatologie CHRU de Brest - Hopital Morvan
Brest, Finistere, France
Service de Dermatologie Centre Hospitalier Universitaire de Nice - Hopital Archet 2
Nice, Provence-Alpes-Côte d'Azur Region, France
CHU de Bordeaux, Hopital Saint-Andre
Bordeaux, France
Hopital Saint-Louis - GH De La Rochelle-Re-Aunis
La Rochelle, France
Hôpital La Timone-Dermatologie
Marseille, France
Hopital de l'Hotel Dieu - CHU de Nantes
Nantes, France
Hôpital Saint Louis, Centre de Santé Sabouraud
Paris, France
Centre Hospitalier Universitaire de Toulouse - Hopital Larrey
Toulouse, France
Universitätsklinikum Tübingen Universitäts-Hautklinik
Tübingen, Baden-Wüttermberg, Germany
Universitätsklinikum Erlangen, Hautklinik
Erlangen, Bavaria, Germany
...and 29 more locations